Acusphere Inc

Healthcare US ACUS

0.0USD
-(-%)

Last update at 2025-05-20T20:00:00Z

52 Week Range

--
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap3.71M
  • Volume125
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-32.41334M
  • Revenue TTM2.68M
  • Revenue Per Share TTM0.57
  • Gross Profit TTM -31.76800M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2008-12-31 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Type yearly yearly yearly yearly yearly
Date 2008-12-31 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Income before tax -67.73400M 51.46M 63.20M 46.43M 30.47M
Minority interest - - - - -
Net income -67.73400M -53.73000M -61.08900M -44.62537M -29.95905M
Selling general administrative 10.70M 16.17M 14.66M 10.47M 27.30M
Selling and marketing expenses - - - - -
Gross profit -31.76800M 2.67M 1.78M 3.43M 1.71M
Reconciled depreciation - - - - -
Ebit -42.47200M -51.46400M -63.20100M -46.43367M -30.47096M
Ebitda - -43.66600M -52.91000M -42.42638M -29.10312M
Depreciation and amortization - 7.80M 10.29M 4.01M 1.37M
Non operating income net other - - - - -
Operating income -42.47200M 52.73M 62.28M 46.18M 30.43M
Other operating expenses - 55.39M 64.06M 49.61M 32.14M
Interest expense 0.00000M 2.05M 2.27M 0.55M 0.13M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00000M 1.00M -1.19000M -1.55129M -0.46819M
Total revenue 2.68M 2.67M 1.78M 3.43M 1.71M
Total operating expenses 45.16M 55.39M 64.06M 49.61M 32.14M
Cost of revenue 34.45M 39.23M 47.91M 33.92M 3.47M
Total other income expense net -25.26200M -1.26300M 0.92M 0.26M 0.04M
Discontinued operations - - - - -
Net income from continuing ops -67.73400M -53.73000M -61.08900M -44.62500M -
Net income applicable to common shares -69.42100M -56.00500M -63.47000M -47.04400M -
Preferred stock and other adjustments - - - - -
Breakdown 2008-12-31 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Type yearly yearly yearly yearly yearly
Date 2008-12-31 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Total assets 23.11M 52.02M 94.82M 95.84M 62.00M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.25M 1.26M 0.84M 1.14M 2.10M
Total liab 51.62M 28.28M 36.37M 38.42M 16.49M
Total stockholder equity -28.50300M 23.74M 58.45M 57.42M 45.51M
Deferred long term liab - - 4.67M 2.58M -
Other current liab 13.93M 3.61M 4.14M 7.91M 8.79M
Common stock -28.50300M 0.46M 0.38M 0.23M 0.18M
Capital stock - - - - -
Retained earnings - -334.87100M -281.14100M -220.05188M -175.42650M
Other liab 14.44M 3.07M 12.37M 8.14M 0.86M
Good will - - - - -
Other assets 5.41M 1.60M 1.84M 3.55M 1.86M
Cash 16.45M 26.10M 59.75M 51.11M 45.18M
Cash and equivalents - - - - -
Total current liabilities 13.93M 18.83M 22.32M 21.24M 13.13M
Current deferred revenue - 4.67M 2.67M 3.43M 3.43M
Net debt - -8.09200M -37.47000M -29.78482M -41.60571M
Short term debt 23.25M 8.56M 12.90M 6.73M 1.07M
Short long term debt 23.25M 4.93M 12.90M 6.73M -
Short long term debt total - 18.01M 22.28M 21.33M 3.57M
Other stockholder equity - 358.14M 678.45M 555.18M 221.67M
Property plant equipment - 23.05M 32.39M 40.03M 12.87M
Total current assets 17.70M 27.37M 60.59M 52.25M 47.28M
Long term investments - - - - -
Net tangible assets -28.50300M 23.73M 58.44M 57.41M -
Short term investments - - - - -
Net receivables - - - - -
Long term debt 23.25M 6.34M 1.68M 9.03M 2.50M
Inventory - - - - -
Accounts payable - 1.99M 2.62M 3.18M 4.24M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -0.02200M -0.35896M -0.91449M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - 0.00700M 0.00700M 0.00700M -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 1.41M 1.78M 1.75M 1.86M
Deferred long term asset charges - - - - -
Non current assets total - 24.65M 34.23M 43.59M 14.73M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2008-12-31 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Type yearly yearly yearly yearly yearly
Date 2008-12-31 2007-12-31 2006-12-31 2005-12-31 2004-12-31
Investments - - - - -
Change to liabilities 0.00000M -0.62800M 2.26M 4.09M 4.98M
Total cashflows from investing activities - -0.99300M -1.22000M -32.86600M -
Net borrowings - -7.50700M -1.35900M 12.19M -
Total cash from financing activities - 9.05M 57.95M 69.48M 22.38M
Change to operating activities - -1.04800M -2.46400M 2.16M -
Net income -67.73400M -53.73000M -61.08900M -44.62537M -29.95905M
Change in cash - -33.64800M 8.64M 5.93M -9.38246M
Begin period cash flow 26.10M 59.75M 51.11M 45.18M 54.56M
End period cash flow - 26.10M 59.75M 51.11M 45.18M
Total cash from operating activities - -41.70700M -48.08900M -30.68250M -19.31922M
Issuance of capital stock - - - - -
Depreciation - 7.80M 10.29M 4.01M 1.37M
Other cashflows from investing activities - 0.00300M -0.13000M 0.11M -
Dividends paid - 2.27M 2.38M 2.22M -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - 18.83M 61.69M 17.62M -
Other cashflows from financing activities - -7.50700M -1.35900M 12.19M 0.00037M
Change to netincome - 3.46M 2.92M 3.68M -
Capital expenditures 0.00000M 1.00M 1.09M 32.98M 12.18M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - -1.67600M -0.20800M 6.25M 9.59M
Stock based compensation - - - - -
Other non cash items - 5.90M 2.92M 3.68M -0.32181M
Free cash flow - -42.70300M -49.17900M -63.66015M -31.50232M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACUS
Acusphere Inc
- -% - - - 1.38 - 1.37 -0.0941
ZTS
Zoetis Inc
-0.335 0.20% 163.31 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR
0.54 2.08% 26.45 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
- -% 136.20 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR
0.07 0.46% 14.34 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

Profile

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.

Acusphere Inc

500 Arsenal Street, Watertown, MA, United States, 02472

Key Executives

Name Title Year Born
Dr. William I. Ramage D.Phil Chief Devel. Officer 1954
Dr. William I. Ramage D.Phil Chief Development Officer 1954

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.